Swiss National Bank Raises Stock Position in UiPath Inc. (NYSE:PATH)

Swiss National Bank increased its stake in shares of UiPath Inc. (NYSE:PATH) by 4.9% during the 4th quarter, Holdings Channel.com reports. The fund owned 1,211,500 shares of the healthcare company’s stock after purchasing an additional 56,600 shares during the quarter. Swiss National Bank’s holdings in UiPath were worth $30,094,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in PATH. Vanguard Group Inc. lifted its stake in shares of UiPath by 7.6% in the third quarter. Vanguard Group Inc. now owns 37,750,773 shares of the healthcare company’s stock valued at $645,916,000 after purchasing an additional 2,673,718 shares during the period. Glenmede Trust Co. NA boosted its stake in shares of UiPath by 3,273.3% during the 3rd quarter. Glenmede Trust Co. NA now owns 1,564,985 shares of the healthcare company’s stock worth $26,777,000 after acquiring an additional 1,518,592 shares in the last quarter. FMR LLC grew its holdings in shares of UiPath by 2.9% in the 3rd quarter. FMR LLC now owns 16,238,176 shares of the healthcare company’s stock worth $277,835,000 after acquiring an additional 463,032 shares during the period. Los Angeles Capital Management LLC increased its stake in UiPath by 179.9% in the 3rd quarter. Los Angeles Capital Management LLC now owns 715,688 shares of the healthcare company’s stock valued at $12,245,000 after purchasing an additional 459,965 shares in the last quarter. Finally, Federated Hermes Inc. boosted its position in UiPath by 857.7% during the fourth quarter. Federated Hermes Inc. now owns 458,126 shares of the healthcare company’s stock worth $11,380,000 after purchasing an additional 410,288 shares in the last quarter. Institutional investors and hedge funds own 62.50% of the company’s stock.

UiPath Stock Down 0.6 %

Shares of NYSE PATH opened at $19.89 on Thursday. The stock has a market capitalization of $11.32 billion, a PE ratio of -117.00 and a beta of 1.01. The firm has a fifty day moving average of $21.60 and a 200-day moving average of $21.78. UiPath Inc. has a 52-week low of $13.30 and a 52-week high of $27.87.

UiPath (NYSE:PATH) last announced its quarterly earnings results on Wednesday, March 13th. The healthcare company reported $0.06 EPS for the quarter, topping the consensus estimate of ($0.04) by $0.10. The company had revenue of $405.25 million during the quarter, compared to analyst estimates of $383.32 million. UiPath had a negative return on equity of 3.29% and a negative net margin of 6.87%. Equities research analysts expect that UiPath Inc. will post -0.04 EPS for the current fiscal year.

Insider Transactions at UiPath

In related news, CFO Ashim Gupta sold 40,000 shares of the company’s stock in a transaction on Thursday, April 4th. The shares were sold at an average price of $21.66, for a total transaction of $866,400.00. Following the completion of the sale, the chief financial officer now directly owns 660,762 shares of the company’s stock, valued at approximately $14,312,104.92. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders sold 96,000 shares of company stock valued at $2,023,440 over the last 90 days. Corporate insiders own 31.03% of the company’s stock.

Analyst Ratings Changes

PATH has been the subject of a number of research analyst reports. Wells Fargo & Company raised their price target on UiPath from $24.00 to $25.00 and gave the company an “equal weight” rating in a research report on Thursday, March 14th. Scotiabank increased their price target on shares of UiPath from $29.00 to $30.00 and gave the company a “sector perform” rating in a research report on Thursday, March 14th. BMO Capital Markets lifted their price objective on UiPath from $24.00 to $28.00 and gave the stock a “market perform” rating in a research report on Thursday, March 14th. Truist Financial reiterated a “buy” rating and set a $32.00 target price on shares of UiPath in a report on Wednesday, March 20th. Finally, KeyCorp started coverage on UiPath in a report on Monday, April 8th. They issued an “overweight” rating and a $27.00 price target for the company. Nine analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat.com, UiPath currently has a consensus rating of “Moderate Buy” and an average target price of $27.41.

About UiPath

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.